Drug
Darotropium bromide clinical trials
Also written GSK233705.
- studies test it
- 11
- open now
- 0
- in phase 3
- 0
- first study started
- 2005
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
11 studies that test it; most in 2008 (5)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses darotropium bromide is read from its arms, and is right about nine times in ten.
Testing it · 11
- Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPDCompletedPhase 2GlaxoSmithKlineNCT00749411Written as GSK233705/GW642444
- Safety And Tolerability Study In Patients With Chronic Obstructive Pulmonary DiseaseCompletedPhase 2GlaxoSmithKlineNCT00376714Written as GSK233705
- A Dose Ascending, Study To Examine The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of GSK233705B.CompletedPhase 2GlaxoSmithKlineNCT00453479Written as GSK233705B
- Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 2GlaxoSmithKlineNCT00676052Written as GSK233705 12.5mcg
- A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects.CompletedPhase 1GlaxoSmithKlineNCT00671216Written as GSK233705
- Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary DiseaseCompletedPhase 1GlaxoSmithKlineNCT00279019Written as GSK233705
- Study To Examine Safety, Tolerability And Pharmacokinetics Of Intravenous Doses And Oral Dose Of GSK233705CompletedPhase 1GlaxoSmithKlineNCT00500461Written as GSK233705
- A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK233705 In Healthy Volunteers.CompletedPhase 1GlaxoSmithKlineNCT00453687Written as GSK233705
- Phase I Study of GSK233705 in Healthy Japanese Male SubjectsCompletedPhase 1GlaxoSmithKlineNCT00964405Written as GSK233705
- A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy SubjectsCompletedPhase 1GlaxoSmithKlineNCT00783003Written as GSK233705 and GW642444
- Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 2GlaxoSmithKlineNCT00422604Written as GSK233705
Codes
What other systems call darotropium bromide · ClinicalTrials.gg INT014541
- UNII (FDA) 2W2V1U785ADAROTROPIUM BROMIDEOne source FDA
- NCI Thesaurus C76000Darotropium BromideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 2W2V1U785A | DAROTROPIUM BROMIDE | One source FDA |
| NCI Thesaurus | C76000 | Darotropium Bromide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.